The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancer

The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancer - The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026520

Enrollment

Registered

2017-03-15

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-muscle invasive bladder cancer

Interventions

enzalutamide administration for four weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: pathologically diagnosed non-muscle invasive bladder cancer patients

Exclusion criteria

Exclusion criteria: history of androgen deprivation therapy

Design outcomes

Primary

Measure	Time frame
Tumor shrinkage 4 weeks after administration	—

Secondary

Measure	Time frame
safety	—

Countries

Japan

Contacts

Public ContactTakashi Kawahara

Tsukuba University Hospital Urology

tkawahar99@gmail.com029-853-3223

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026